Agios Pharmaceuticals’ Post

ISB 1342, Ichnos’ CD38 x CD3 T-cell engager for relapsed/refractory multiple myeloma, is highlighted on the cover of the American Society of Hematology's journal, Blood. In this latest print edition of the journal, you’ll find our latest research article, Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed/refractory multiple myeloma: https://lnkd.in/ezwyFBUE

We are excited to provide updated clinical safety and efficacy data from 7 transfusion-dependent beta thalassemia patients treated with renizgamglogene autogedtemcel (reni-cel) in the Phase 1/2 EdiThal clinical trial at European Hematology Association (EHA) annual congress. Treated patients had early and robust increases of total hemoglobin (Hb) and fetal hemoglobin, with total Hb rising to or above the transfusion independence threshold of 9.0 g/dL. All patients have been transfusion free for a range of 4.1 to 12.8 months after receiving the last red blood cell transfusion at 0.5–2.2 months post-reni-cel infusion. Reni-cel was well-tolerated and continues to demonstrate a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant. #BetaThalassemia #Biotechnology #Cas12a #CellTherapy #ClinicalTrials #CRISPR #EHA #GeneEditing #Hematology

Thanks, Richard! Today, I presented my recent results and insights on transcriptomic MYC activation in CLL. Long story short, high MYC transcriptomic activation is associated with increased interactions with the TME, suggesting MYC as an orchestrator of TME interactions and explaining why it is linked to various cellular processes. #eha #eha2024

Preparing the last details of the podcast interviews to record at the #EHA2024 European Hematology Association congress.

some basics of micro

#Congress | 🔎 What subjects were amplified by #HCPs through social media during #EHA2023? In June, took place the European Hematology Association (EHA) 2023 Hybrid Congress. The following pages provide a brief overview of the volume of conversations, the share of voice of medical conditions most discussed, or top hashtags. Moreover, discover a focus on #multiplemyeloma with the topics of discussions. Access the SML EHA2023 full report by clicking this link 👉 https://lnkd.in/eV8hsx9B

Last week I presented the first results of the phase 2 ICON study at the European Hematology Association (EHA) conference in Madrid. In the ICON study, relapsed/refractory multiple myeloma patients were treated with iberdomide, low-dose cyclophosphamide and dexamethasone. Iberdomide is a novel cereblon E3 ligase modulator (CELMoD™) with improved direct anti-myeloma activity and immune-stimulatory effects. This treatment regimen resulted in a ORR of 82% and a median PFS of 17.8 months in patients with 2-4 prior lines of therapy. This fully oral, well tolerated, and active combination warrants further evaluation in RRMM. The full abstract is available online: https://lnkd.in/eUqb4Vaq What an interesting conference the #EHA2024 has been! Thanks to all co-authors and my supervisors Niels Van De Donk, Sonja Zweegman and Tuna Mutis.

Discover the latest developments in myeloma research from the Annual American Society of Hematology meeting. Clinical trial investigators share their abstract presentations from ASH delving deep into the key research takeaways. Watch Now: https://lnkd.in/gaawhHcq #ASH23

Can BCMA-Targeting therapies improve survival in patients with relapsed/recurring #MultipleMyeloma? Learn more at the Hematology Advisor Institute, and earn CME/CE. https://brnw.ch/21wBDVc

Mark your calendars for a live webinar hosted by Fortis Institute of Blood Disorder on Innovations in Hematology. Join us on May 17th, 2024, from 7 PM to 8 PM and gain invaluable knowledge from leading specialists Dr. Jayastu Senapati and Dr. Nikhil M Kumar. Discover new technologies and innovative practices that are shaping the future of hematology. #AtFortisWeCare #FortisHealthcare #Webinar